Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE: BMY) announced the FDA has accepted the New Drug Application for iberdomide in relapsed or refractory multiple myeloma with a PDUFA target action date of August 17, 2026. The submission is based on MRD negativity results from the Phase 3 EXCALIBER-RRMM study (Stage 2 ~664 patients) and received Breakthrough Therapy designation.
The review is part of FDA Project Orbis for concurrent international review; EXCALIBER remains ongoing and PFS data are still maturing.
Bristol Myers Squibb (NYSE: BMY) reported fourth quarter and full-year 2025 financial results and will host a conference call and live audio webcast at 8:00 a.m. ET on February 5, 2026. A replay will be available on the company’s investor site about three hours after the call.
Investor and media contact emails are provided for follow-up.
Bristol Myers Squibb (NYSE: BMY) announced a partnership with soccer Hall-of-Famer Kasey Keller, who for the first time is publicly sharing his non-Hodgkin lymphoma journey and one-time treatment with Breyanzi (lisocabtagene maraleucel) to raise awareness on World Cancer Day.
The release highlights Breyanzi’s five FDA-approved indications, a 3-year follow-up showing a 62% average reduction in risk versus standard care, and Important Safety Information including Boxed WARNINGS for CRS, neurologic toxicities, and secondary hematologic malignancies.
Bristol Myers Squibb (NYSE: BMY) launched an educational campaign, "Change the Target. Change What’s Possible.", developed with Johnson & Johnson to highlight unmet needs in cardiovascular and thromboembolic care and the emerging research interest in factor XIa (FXIa) as a potential target.
The program cites that 40% of atrial fibrillation patients are untreated or undertreated and that roughly 25% of strokes are recurrent, noting bleeding risk as a key gap in current therapies. Resources are available at www.factorxi.com.
Bristol Myers Squibb (NYSE: BMS) announced a collaboration with Microsoft on January 20, 2026 to deploy U.S. FDA-cleared radiology AI algorithms for lung cancer detection via Microsoft’s Precision Imaging Network. The initiative aims to automatically analyze X-ray and CT images to surface hard-to-detect lung nodules, accelerate identification of potential Non‑Small Cell Lung Cancer (NSCLC) cases, and route patients into care pathways.
The program emphasizes expanding early detection and follow-up in medically underserved communities, leveraging workflow tools to address that >50% of patients with incidental findings are lost to follow-up and noting Microsoft’s network reaches more than 80% of U.S. hospitals.
Bristol Myers Squibb (NYSE: BMY) announced positive topline Phase 3 SCOUT-HCM results showing Camzyos (mavacamten) met the primary endpoint with a statistically significant reduction in Valsalva LVOT gradient at Week 28 versus placebo in adolescents (ages 12 to <18).
The 44‑patient trial also met multiple secondary endpoints, reported safety consistent with the adult profile with no new signals, and continues into active treatment and a long‑term extension (totaling up to 200 weeks).
Bristol Myers Squibb (NYSE: BMY) will present at J.P. Morgan’s 44th Annual Healthcare Conference on Monday, January 12, 2026. The company's presentation and a fireside chat will begin at 7:30 a.m. PST / 10:30 a.m. ET.
The event will be webcast live at http://investor.bms.com, with presentation materials available at the start of the webcast. A replay and archived edition will be available after the event.
Bristol Myers Squibb (NYSE: BMS) announced an agreement with the U.S. government to improve affordability and supply resilience for Eliquis (apixaban).
Key items: Eliquis will be provided free to the Medicaid program starting January 1, 2026; the company will donate more than seven tons of Eliquis active pharmaceutical ingredient (API) to the U.S. Strategic Active Ingredient Reserve at no cost; BMS will receive three years of tariff relief; and BMS will enable direct-to-patient discounted access (about 80% off list price) for several branded medicines. The agreement’s specific commercial terms remain confidential. BMS reaffirmed a prior commitment to invest $40 billion in the United States over five years and said it will expand domestic production to support onshoring.
Bristol Myers Squibb (NYSE: BMY) will report results for the fourth quarter of 2025 on Thursday, February 5, 2026. Company executives will review financial results on a conference call beginning at 8:00 a.m. ET, with a live webcast available to investors and the public at http://investor.bms.com. Presentation materials will be posted to the same site before the call.
A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. Contact emails: media@bms.com and investor.relations@bms.com.
Bristol Myers Squibb (NYSE: BMY) announced on December 11, 2025 that the U.S. FDA has accepted and granted priority review to the supplemental BLA for Opdivo (nivolumab) plus AVD for previously untreated Stage III or IV classical Hodgkin lymphoma in adults and pediatric patients 12 years and older. The FDA assigned a PDUFA target action date of April 8, 2026. The filing is supported by the randomized Phase 3 SWOG S1826 (CA2098UT) study, which lists progression-free survival as the primary endpoint and overall survival among key secondary endpoints. The study is sponsored by the National Cancer Institute and co-sponsored and supplied by Bristol Myers Squibb.